GRT-002
Itch, Allergy, Inflammation (Type II Inflammation)
PreclinicalActive
Key Facts
Indication
Itch, Allergy, Inflammation (Type II Inflammation)
Phase
Preclinical
Status
Active
Company
About Granite Bio
Granite Bio is a private, pre-revenue biotech developing novel antibody therapies for inflammatory, autoimmune, and fibrotic diseases. Its lead asset, GRT-001, is a Phase 1b 'innate Rituximab' targeting pro-inflammatory monocytes, while GRT-002 is a preclinical anti-IL-3 program. The company is backed by top-tier venture capital firms and led by a team with deep industry experience in immunology and drug development.
View full company profile